Overview

Relative Bioavailability Study of Emodepside IR-tablets and Solution

Status:
Completed
Trial end date:
2018-03-26
Target enrollment:
Participant gender:
Summary
This study evaluates 2 new immediate release (IR)-tablet formulations of emodepside and they will be compared to the oral liquid service formulation (LSF) used in the FIH Single Ascending Dose study (DNDi-EMO-001 study) (CT.gov identifier: NCT02661178)
Phase:
Phase 1
Details
Lead Sponsor:
Drugs for Neglected Diseases
Collaborators:
Bayer
Bill and Melinda Gates Foundation
Treatments:
Emodepside
Praziquantel
Toltrazuril